MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027Third Quarter Revenue of $3.6 Million; 2026 Revenue Outlook Dependent on Ongoing U.S. Government DiscussionsBalance Sheet Strengthened by $17.25 Million in Gross Proceeds fro…